(Reuters) - Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs. OncoMed will get …
If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing third-quarter revenue expectations, and lowering its full …
Celgene Corporation's (NASDAQ:CELG) stock were down more than 5% in premarket trade following news of a drug development disappointment. In after-hours on Thursday, the pharmaceutical firm announced it would not take a …
Celgene Corp. (CELG) announced after the close Thursday that its Phase 3 study of Revlimid plus rituximab did not achieve superiority in the co-primary endpoints in patients with previously untreated follicular lymphoma. The stock is …
At $95.64, the stock has room to fall short-term, even if the positive trends remain in place: “Correction support” comes into play at the $89.70-$91.30 range and the long-term uptrend line comes into play at around $83. Technicians still call …
Biotech stocks and the related ETFs have been the star performers this year despite some temporary glitches and …
A quick analysis of Celgene Corporation (NASDAQ: CELG) stock history reveals three distinct stages with four stock splits along the way. These stages led to the company becoming what the following chart shows it to be -- one of the …